다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of virological methods, v.236, 2016년, pp.105 - 110
Tseng, Y.S. , Vliet, K.V. , Rao, L. , McKenna, R. , Byrne, B.J. , Asokan, A. , Agbandje-McKenna, M.
AI-Helper
Adeno-associated viruses (AAVs) are promising viral vectors for therapeutic gene delivery, and the approval of an AAV1 vector for the treatment of lipoprotein lipase deficiency has heralded a new and exciting era for this system. However, preclinical and clinical studies show that neutralization fro...
Nat. Commun. Adachi 5 3075 2014 10.1038/ncomms4075 Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing
Gene Ther. Bainbridge 15 1191 2008 10.1038/gt.2008.117 Success in sight: the eyes have it! Ocular gene therapy trials for LCA look promising
Hum. Gene Ther. Bell 22 985 2011 10.1089/hum.2010.194 Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs
Mol. Ther. Bevan 19 1971 2011 10.1038/mt.2011.157 Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders
J. Natl. Cancer Inst. Blacklow 40 319 1968 Serologic evidence for human infection with adenovirus-associated viruses
Hum. Gene Ther. Boutin 21 704 2010 10.1089/hum.2009.182 Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors
Proc. Natl. Acad. Sci. U. S. A. Brantly 106 16363 2009 10.1073/pnas.0904514106 Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Clin. Vaccine Immunol. Calcedo 18 1586 2011 10.1128/CVI.05107-11 Adeno-associated virus antibody profiles in newborns, children, and adolescents
J. Infect. Dis. Calcedo 199 381 2009 10.1086/595830 Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
J. Neurosci. Cearley 27 9928 2007 10.1523/JNEUROSCI.2185-07.2007 A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease
J. Virol. Methods Chahal 196 163 2014 10.1016/j.jviromet.2013.10.038 Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery
J. Virol. Chirmule 74 2420 2000 10.1128/JVI.74.5.2420-2425.2000 Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
Hyperlipidaemia Cardiovasc. Dis. Daniel Gaudet 23 310 2012 Gene therapy for lipoprotein lipase deficiency
Gene Ther. Federici 19 852 2012 10.1038/gt.2011.130 Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
Hum. Gene Ther. Ferreira 25 180 2014 10.1089/hum.2013.169 Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy
Mol. Ther. Fu 19 1025 2011 10.1038/mt.2011.34 Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery
J. Virol. Gao 78 6381 2004 10.1128/JVI.78.12.6381-6388.2004 Clades of adeno-associated viruses are widely disseminated in human tissues
J. Gene Med. Ginn 15 65 2013 10.1002/jgm.2698 Gene therapy clinical trials worldwide to 2012 - an update
Mol. Ther. Gray 19 1058 2011 10.1038/mt.2011.72 Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates
J. Virol. Gurda 86 7739 2012 10.1128/JVI.00218-12 Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8
Hum. Gene Ther. Halbert 17 440 2006 10.1089/hum.2006.17.440 Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors
J. Gen. Virol. Harbison 93 347 2012 10.1099/vir.0.035113-0 Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5
Mol. Ther. Hurlbut 18 1983 2010 10.1038/mt.2010.175 Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy
J. Virol. Methods Kuck 140 17 2007 10.1016/j.jviromet.2006.10.005 Development of AAV serotype-specific ELISAs using novel monoclonal antibodies
Acta Crystallogr. Sect F Struct. Biol. Cryst. Commun. Lane 61 558 2005 10.1107/S1744309105014132 Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8
Gene Ther. Li 19 288 2012 10.1038/gt.2011.90 Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia
J. Med. Virol. Liu 85 1550 2013 10.1002/jmv.23647 The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector
N. Engl. J. Med. Maguire 358 2240 2008 10.1056/NEJMoa0802315 Safety and efficacy of gene transfer for Leber’s congenital amaurosis
Lancet Maguire 374 1597 2009 10.1016/S0140-6736(09)61836-5 Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
Nat. Med. Manno 12 342 2006 10.1038/nm1358 Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Hum. Gene Ther. Methods Martin 24 253 2013 10.1089/hgtb.2013.046 Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production
Ann. Neurol. Mendell 66 290 2009 10.1002/ana.21732 Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins
Hum. Gene Ther. Mietzsch 25 212 2014 10.1089/hum.2013.184 OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy
Acta Crystallogr. Sect F Struct. Biol. Cryst. Commun. Mitchell 65 715 2009 10.1107/S1744309109021460 Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9
Blood Nathwani 107 2653 2006 10.1182/blood-2005-10-4035 Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver
Blood Nathwani 109 1414 2007 10.1182/blood-2006-03-010181 Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates
N. Engl. J. Med. Nathwani 365 2357 2011 10.1056/NEJMoa1108046 Adenovirus-associated virus vector-mediated gene transfer in hemophilia B
J. Virol. Ng 84 12945 2010 10.1128/JVI.01235-10 Structural characterization of the dual glycan binding adeno-associated virus serotype 6
Pollack 2012 European Agency Backs Approval of a Gene Therapy
Methods Mol. Biol. Sands 807 141 2011 10.1007/978-1-61779-370-7_6 AAV-mediated liver-directed gene therapy
Blood Scallan 107 1810 2006 10.1182/blood-2005-08-3229 Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
Front. Neuroanat. Schuster 8 42 2014 10.3389/fnana.2014.00042 Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse
Hum. Gene Ther. Smith 24 630 2013 10.1089/hum.2012.250 Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes
J. Virol. Sonntag 85 12686 2011 10.1128/JVI.05359-11 The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes
Mol. Ther. Spampanato 19 860 2011 10.1038/mt.2010.299 Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder
Inflamm. Bowel Dis. van der Marel 17 2436 2011 10.1002/ibd.21673 Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy
J. Immunol. Veron 188 6418 2012 10.4049/jimmunol.1200620 Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors
Hum. Gene Ther. Wang 22 1389 2011 10.1089/hum.2011.031 Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors
Expert Opin. Biol. Ther. Wierzbicki 13 7 2013 10.1517/14712598.2013.738663 Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
J. Virol. Wistuba 69 5311 1995 10.1128/JVI.69.9.5311-5319.1995 Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins
J. Virol. Wobus 74 9281 2000 10.1128/JVI.74.19.9281-9293.2000 Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection
Gene Ther. Xue 17 83 2010 10.1038/gt.2009.113 AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson’s disease
Mol. Ther. Zhang 11 866 2005 10.1016/j.ymthe.2005.02.014 Genetic analysis of the antibody response to AAV2 and factor IX
Mol. Ther. Zhang 19 1440 2011 10.1038/mt.2011.98 Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.